# Pharmacogenomic Decision Support With GeneSight Psychotropic to Guide the Treatment With Antipsychotics

> **NCT02573168** · NA · COMPLETED · sponsor: **St. Joseph's Healthcare Hamilton** · enrollment: 103 (actual)

## Conditions studied

- Schizophrenia
- Schizoaffective Disorder

## Interventions

- **GENETIC:** GeneSight Psychotropic (GEN)
- **GENETIC:** Enhanced-GeneSight Psychotropic (E-GEN)
- **OTHER:** Treatment as Usual (TAU)

## Key facts

- **NCT ID:** NCT02573168
- **Lead sponsor:** St. Joseph's Healthcare Hamilton
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01
- **Primary completion:** 2019-07
- **Final completion:** 2020-09
- **Target enrollment:** 103 (ACTUAL)
- **Last updated:** 2020-11-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02573168

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02573168, "Pharmacogenomic Decision Support With GeneSight Psychotropic to Guide the Treatment With Antipsychotics". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02573168. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*